Crovalimab (anti-Complement C5) - Primary antibody, specific to C5, Human IgG1, INHIBITOR of Complement C5 inhibitor, INHIBITOR of Complement C5 inhibitor

CAS: 1917321-26-6 Cat. No.: Ab182862

GRADE & PURITY Animal Free, Carrier Free, Recombinant, Validated, ExactAb™, Low Endotoxin, Azide Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Application

Animal Model, ELISA, Flow Cytometry, Functional Assay

Host species

Human

Reactive species

Human

Isotype

Human IgG1

Conjugation

Unconjugated

Descripción general

Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Specifications

Product Name

Crovalimab (anti-Complement C5) - Primary antibody, specific to C5, Human IgG1, INHIBITOR of Complement C5 inhibitor

Sinónimos

Anaphylatoxin C5a analog antibody | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody | C5 antibody | C5a anaphylatoxin antibody | C5a antibody | C5b antibody | CO5_HUMAN antibody | Complement C5 alpha'' chain antibody | Complemen

Especificaciones y pureza

Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Especies hospedadoras

Human

Especificidad

C5

Conjugación

Unconjugated

Grado

Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated

Tipo de acción

INHIBITOR

Mecanismo de acción

INHIBITOR of Complement C5 inhibitor

Isotipo

Human IgG1

Tipo de cadena ligera

kappa

SDS-PAGE

26.4 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 190.6 kDa, under non-reducing conditions.

Método de purificación

Protein A purified

Concentración

See COA

CAS

1917321-26-6

Almacenamiento y envío

Forma

Liquid

Condiciones de almacenamiento de almacenamiento

Store at -80°C,Avoid repeated freezing and thawing

Enviado en

Dry ice packs + Cold packs

Estabilidad y almacenamiento

Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Imágenes

ELISA: Crovalimab (anti-Complement C5) (Ab182862)

Crovalimab (anti-Complement C5) (Ab182862) - ELISA
Immobilized Human Complement C5 Protein at 2.0 μg/mL can bind Crovalimab (anti-Complement C5) (Ab182862) with the EC50 of 9.58 ng/mL.

SEC: Crovalimab (anti-Complement C5) (Ab182862)

Crovalimab (anti-Complement C5) (Ab182862) - SEC
The purity of Crovalimab (anti-Complement C5) (Ab182862) is more than 95% verified by HPLC.

Objetivos asociados (humanos)

C5 Tclin Complement C5 (0 Activities)

Discover Target: C5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mecanismos de acción